For support read our articles, submit a ticket, email. Healthcare provider time should not be undervalued and iScribe helps to maximize efficiency and productivity unlike any other solution available today. Remember my login information Forgot your password Copyright 2023 Experity, Inc. iScribe’s modern mobile user experience allows the clinical documentation to be completed at the point of care without taking away from the provider / patient experience. Physicians can complete their encounter without having to wait until the end of the day or after office hours and there is no waiting for pending transcription. IScribe reduces the time that healthcare providers typically spend in the EHR allowing more time to take care of patients. ( For each Allocation Base used in Itens 8.3.2 and 8.3.3, Iscribe on i continuation sheet. iScribe users have saved $15,000 - $25,000 per provider per year in reduced transcription costs. By using the real-time speech-to-text feature, transcription costs can be eliminated. Users can dictate directly into the appropriate sections (CC, HPI, ROS, PE, A/P) on the mobile device and save their documentation immediately into their EHR. Information reported to the hotline in the past has helped to eliminate certain fraudulent activities and protect State resources. With iScribe’s real-time speech-to-text dictation feature, users can visually see the dictated text directly on the screen as they are speaking. The Maryland General Assembly’s Office of Legislative Audits operates a toll-free fraud hotline to receive allegations of fraud and/or abuse of State government resources. We leverage industry leading speech-to-text technology to increase provider efficiency and productivity while eliminating expensive transcription costs. IScribe is an easy-to-use app that gives providers anytime/anywhere access via iPhone, iPad, or Mac to view and enter clinical information for patients. IScribe cures physician burnout and allows physicians to focus on caring for patients rather than the computer screen.
0 Comments
Leave a Reply. |